[6-K] Haleon plc American Current Report (Foreign Issuer)

Rhea-AI Filing Summary

Haleon plc reported its total issued share capital and voting rights. The company has 8,959,221,411 ordinary shares of
each, of which 3,880,205 are held in treasury, leaving 8,955,341,206 ordinary shares with voting rights. Shareholders and others with notification obligations should use the voting-rights figure as the denominator for FCA notification calculations and may send notifiable interests to company.secretary@haleon.com. The filing also provides a brief company description noting Haleon (LSE/NYSE: HLN) is a global consumer health company with major brands across Oral Health, VMS, Pain Relief, Respiratory, Digestive and Therapeutic Skin Health.

Positive

• Exact voting-rights denominator provided (8,955,341,206 shares), enabling accurate FCA notification calculations
• Treasury shares disclosed (3,880,205), clarifying the difference between issued and voting shares
• Contact provided for notifiable interests (company.secretary@haleon.com), aiding transparency and compliance

Negative

• None.

Insights

Financial Analyst

TL;DR: Routine capital structure disclosure provides the exact share count and voting base for regulatory notifications; no financial performance data included.

The document supplies the precise number of issued shares, treasury shares and shares carrying voting rights, which is necessary for calculating ownership thresholds under disclosure rules. This is administrative but important for accurate shareholder notification compliance. It does not contain earnings, balance-sheet figures, transactions, or forward guidance, so it has limited direct market impact.

Corporate Governance Expert

TL;DR: Clear disclosure of voting share denominator aids transparency and supports compliance with FCA notification requirements.

The filing succinctly states the voting-rights denominator and provides a contact for notifications, reflecting standard governance practice to ensure market participants can determine reporting obligations. The inclusion of treasury share totals clarifies outstanding voting power. No governance changes or director transactions are reported.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of September 2025

Commission File Number: 001-41411

Haleon plc

(Translation of registrant’s name into English)

Building 5, First Floor, The Heights,

Weybridge, Surrey, KT13 0NY

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

EXHIBIT INDEX

Exhibit Number	Description
99.1	01 September 2025 - “Total Voting Rights and Capital”

99.1

Haleon plc: Total Voting Rights and Capital

1 September 2025: As at 31 August 2025 the total number of shares issued by Haleon plc ("Haleon" or the "Company") is 8,959,221,411 ordinary shares of £0.01 each, of which 3,880,205 are held as treasury shares.

Therefore, the number of ordinary shares with voting rights is 8,955,341,206 and this figure should be used by shareholders (and others with notification obligations) as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

Notifiable interests in Haleon may be sent to: company.secretary@haleon.com

Amanda Mellor

Company Secretary

About Haleon

Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.

For more information, please visit www.haleon.com. 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		HALEON PLC (Registrant)
Date: September 01, 2025	By:	/s/ Amanda Mellor
		Name:	Amanda Mellor
		Title:	Company Secretary

FAQ

How many ordinary shares does Haleon (HLN) have issued?

Haleon has 8,959,221,411 ordinary shares issued.

How many Haleon shares are held as treasury shares?

3,880,205 ordinary shares are held as treasury shares.

What is the number of Haleon ordinary shares with voting rights?

The number of ordinary shares with voting rights is 8,955,341,206.

Who should I contact to report a notifiable interest in Haleon (HLN)?

Notifiable interests may be sent to company.secretary@haleon.com.

What business does Haleon (HLN) operate in?

Haleon is a global consumer health company with brands in Oral Health, VMS, Pain Relief, Respiratory, Digestive and Therapeutic Skin Health.